Thiogenesis Therapeutics Corp. moves to OTCQX Best Market, providing transparency for U.S. investors.

From GlobeNewswire: 2025-02-12 07:00:00

OTC Markets Group Inc. announced that Thiogenesis Therapeutics Corp. has qualified to trade on the OTCQX Best Market, upgrading from the Pink market. Thiogenesis will begin trading under the symbol “TTIPF,” providing U.S. investors with financial disclosure and real-time quotes. This move allows companies to provide transparent trading for U.S. investors by meeting high financial standards and corporate governance. Thiogenesis Therapeutics is a clinical-stage biopharmaceutical company developing sulfur-containing prodrugs to treat pediatric diseases with unmet medical needs. The company’s initial target indications include MELAS, Leigh’s syndrome, Rett syndrome, and pediatric MASH.

OTC Markets Group Inc. operates regulated markets for trading 12,000 U.S. and international securities, providing critical market infrastructure for broker-dealers. The company’s data-driven disclosure standards support OTCQX Best Market, OTCQB Venture Market, and Pink Open Market. OTC Link Alternative Trading Systems (ATSs) offer efficient access to the U.S. financial markets, with OTC Link ATS, OTC Link ECN, and OTC Link NQB being SEC-regulated and operated by OTC Link LLC. This model creates better-informed and more efficient markets for investors and companies alike.



Read more at GlobeNewswire: OTC Markets Group Welcomes Thiogenesis Therapeutics, Corp.